{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:44:36Z","timestamp":1782492276766,"version":"3.54.5"},"reference-count":84,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Hematology Association"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In the era of personalized medicine there is an increasing need for the assessment of patient-reported outcomes (PROs) to become a standard of patient care. Patient-reported outcome measures (PROM) are important in assessing significant and meaningful changes as a result of an intervention based on a patient\u2019s own perspective. It is well established that active multiple myeloma (MM) can be characterized by a high burden of disease and treatment-related symptoms, with considerable worsening of quality of life (QoL). In general, and over the past decade, the focus has shifted to obtaining the most durable remissions with the best QoL as primary goals for MM treatment. Patients place considerable value on their QoL and communicating about QoL data prior to treatment decisions allows them to make informed treatment choices. Consequently, optimization of QoL of patients with MM is an important therapeutic goal and the incorporation of PROs into clinical trials has the potential of improving treatment outcomes. In this regard, guidance for the use and reporting of PROMs in MM in clinical trials is warranted. Under the auspices of the European Hematology Association, evidence-based guidelines for the use and reporting of PROs in patients with MM have been developed according to the EHA\u2019s core Guidelines Development Methodology. This document provides general considerations for the choice of PROMs in MM clinical trials as well as a series of recommendations covering a selection of PROMs in MM clinical trials; the mode of administration; timing of assessments; strategies to minimize missing data; sample size calculation; reporting of results; and interpretation of results.<\/jats:p>","DOI":"10.3390\/cancers15245764","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T08:47:26Z","timestamp":1702025246000},"page":"5764","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials"],"prefix":"10.3390","volume":"15","author":[{"given":"Edward","family":"Laane","sequence":"first","affiliation":[{"name":"Hematology-Oncology Clinic, Tartu University, 50406 Tartu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-5699","authenticated-orcid":false,"given":"Sam","family":"Salek","sequence":"additional","affiliation":[{"name":"School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9238-5734","authenticated-orcid":false,"given":"Esther Natalie","family":"Oliva","sequence":"additional","affiliation":[{"name":"U.O.C. Ematologia, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, 89124 Reggio di Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8700-8598","authenticated-orcid":false,"given":"Christine","family":"Bennink","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Clavreul","sequence":"additional","affiliation":[{"name":"Myeloma Patients Europe, 1050 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G","family":"Richardson","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University of Cologne, 50923 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Ionova","sequence":"additional","affiliation":[{"name":"Quality of Life Unit, Saint Petersburg State University Hospital, 190103 Saint Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical Predictors of Long-Term Survival in Newly Diagnosed Transplant Eligible Multiple Myeloma\u2014An IMWG Research Project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_5","unstructured":"MPE (2023, May 08). Myeloma Diagnosis across Europe: The Diagnosis Experiences of European Myeloma Patients and Perspectives from European Haematologists. Available online: https:\/\/www.mpeurope.org\/wp-content\/uploads\/2022\/09\/MPE-report_Myeloma-Diagnosis-Across-Europe.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"844779","DOI":"10.3389\/fonc.2022.844779","article-title":"Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results","volume":"12","author":"Bertamini","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A Large Meta-Analysis Establishes the Role of MRD Negativity in Long-Term Survival Outcomes in Patients with Multiple Myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to Cure Multiple Myeloma","volume":"100","author":"Paiva","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/17474086.2019.1613886","article-title":"Quality of Life in Multiple Myeloma: Considerations and Recommendations","volume":"12","author":"Seitzler","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1046\/j.1365-2141.1999.01651.x","article-title":"Prognostic Evaluation in Multiple Myeloma: An Analysis of the Impact of New Prognostic Factors","volume":"106","author":"Turesson","year":"1999","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00019053-199916040-00002","article-title":"Therapeutic Options in the Treatment of Multiple Myeloma: Pharmacoeconomic and Quality-of-Life Considerations","volume":"16","author":"Gulbrandsen","year":"1999","journal-title":"Pharmacoeconomics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1600-0609.2008.01126.x","article-title":"Psychosocial QOL Is an Independent Predictor of Overall Survival in Newly Diagnosed Patients with Multiple Myeloma","volume":"81","author":"Ludwig","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","article-title":"Symptom Burden, Perceived Control, and Quality of Life among Patients Living with Multiple Myeloma","volume":"18","author":"Zaleta","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ramsenthaler, C., Osborne, T.R., Gao, W., Siegert, R.J., Edmonds, P.M., Schey, S.A., and Higginson, I.J. (2016). The Impact of Disease-Related Symptoms and Palliative Care Concerns on Health-Related Quality of Life in Multiple Myeloma: A Multi-Centre Study. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2410-2"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12882","article-title":"A Systematic Review of Health-Related Quality of Life in Longitudinal Studies of Myeloma Patients","volume":"99","author":"Nielsen","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.17410","article-title":"Guidelines on the Diagnosis, Investigation and Initial Treatment of Myeloma: A British Society for Haematology\/UK Myeloma Forum Guideline","volume":"193","author":"Sive","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"686165","DOI":"10.3389\/fmed.2021.686165","article-title":"Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study","volume":"8","author":"Janssens","year":"2021","journal-title":"Front. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1007\/s00520-022-06979-7","article-title":"Patient Perspectives on Symptoms, Health-Related Quality of Life, and Treatment Experience Associated with Relapsed\/Refractory Multiple Myeloma","volume":"30","author":"Nathwani","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse Symptom Event Reporting by Patients vs. Clinicians: Relationships with Clinical Outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3324\/haematol.2015.127860","article-title":"Health-Related Quality of Life in Patients with Multiple Myeloma\u2014Does It Matter?","volume":"100","author":"Kvam","year":"2015","journal-title":"Haematologica"},{"key":"ref_22","unstructured":"Novik, A., Salek, S., and Ionova, T. (2012). Guidelines Patient-Reported Outcomes in Hematology, European Hematology Association."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/17474086.2019.1645005","article-title":"Towards the Integration of Patient-Reported Outcomes into the Global Clinical Management of Multiple Myeloma","volume":"12","author":"Niscola","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_24","unstructured":"FDA (2023, May 15). U.S. Food and Drug Administration (2009) Guidance for Industry\u2014Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, Available online: https:\/\/www.fda.gov\/media\/77832\/download."},{"key":"ref_25","unstructured":"FDA (2023, May 15). Core Patient-Reported Outcomes in Cancer Clinical Trials, Guidance for Industry, Available online: https:\/\/www.fda.gov\/Regulatory-Information\/Search-Fda-Guidance-Documents\/Core-Patient-Reported-Outcomes-Cancer-Clinical-Trials."},{"key":"ref_26","unstructured":"European Medicines Agency (2005). Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products."},{"key":"ref_27","unstructured":"EMA (2023, May 15). European Medicines Agency Appendix 2 to the Guideline on the Evaluation of Anticancer Medicinal Products in Man. The Use of Patient-Reported Outcome (PRO) Measures in Oncology Studies, Available online: https:\/\/www.ema.europa.eu\/En\/Documents\/Other\/Appendix-2-Guideline-Evaluation-Anticancer-Medicinal-Products-Man_en.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jval.2018.09.2842","article-title":"A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012\u20132016)","volume":"22","author":"Gnanasakthy","year":"2019","journal-title":"Value Health"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.healthpol.2022.01.013","article-title":"Promoting Innovation While Controlling Cost: The UK\u2019s Approach to Health Technology Assessment","volume":"126","author":"Anderson","year":"2022","journal-title":"Health Policy"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","article-title":"COSMIN Guideline for Systematic Reviews of Patient-Reported Outcome Measures","volume":"27","author":"Prinsen","year":"2018","journal-title":"Qual. Life Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Salek, S., Ionova, T., Oliva, E.N., Andreas, M., Skoetz, N., Kreuzberger, N., and Laane, E. (2022). The Reporting, Use, and Validity of Patient-Reported Outcomes in Multiple Myeloma in Clinical Trials: A Systematic Literature Review. Cancers, 14.","DOI":"10.3390\/cancers14236007"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0609.2011.01665.x","article-title":"Responsiveness and Minimal Important Score Differences in Quality-of-Life Questionnaires: A Comparison of the EORTC QLQ-C30 Cancer-Specific Questionnaire to the Generic Utility Questionnaires EQ-5D and 15D in Patients with Multiple Myeloma","volume":"87","author":"Kvam","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41408-021-00543-y","article-title":"Review of Patient-Reported Outcomes in Multiple Myeloma Registrational Trials: Highlighting Areas for Improvement","volume":"11","author":"Fernandes","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clml.2022.01.009","article-title":"Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published between 2014 and 2021","volume":"22","author":"Efficace","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health-Related Quality of Life with Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","article-title":"Health-Related Quality of Life in Patients given Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b-2, Open-Label Study","volume":"9","author":"Martin","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15759","article-title":"Methodological Aspects of Health-Related Quality of Life Measurement and Analysis in Patients with Multiple Myeloma","volume":"185","author":"Nielsen","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clml.2023.03.005","article-title":"Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review","volume":"23","author":"Fonseca","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","article-title":"EQ-5D and the EuroQol Group: Past, Present and Future","volume":"15","author":"Devlin","year":"2017","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"EuroQol Group (1990). EuroQol\u2014A New Facility for the Measurement of Health-Related Quality of Life. Health Policy, 16, 199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40258-013-0035-z","article-title":"A Pilot Discrete Choice Experiment to Explore Preferences for EQ-5D-5L Health States","volume":"11","author":"Norman","year":"2013","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s11136-020-02644-w","article-title":"A Head-to-Head Comparison of Measurement Properties of the EQ-5D-3L and EQ-5D-5L in Acute Myeloid Leukemia Patients","volume":"30","author":"Yu","year":"2021","journal-title":"Qual. Life Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0959-8049(01)00448-8","article-title":"Quality of Life Research within the EORTC\u2014The EORTC QLQ-C30","volume":"38","author":"Fayers","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ijc.1439","article-title":"The EORTC Core Quality of Life Questionnaire (QLQ-C30, Version 3.0) in Terminally Ill Cancer Patients under Palliative Care: Validity and Reliability in a Hellenic Sample","volume":"94","author":"Kyriaki","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2141.1996.352889.x","article-title":"Measurement of Health-Related Quality of Life in Multiple Myeloma. Nordic Myeloma Study Group","volume":"92","author":"Eika","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An International Field Study of the Reliability and Validity of a Disease-Specific Questionnaire Module (the QLQ-MY20) in Assessing the Quality of Life of Patients with Multiple Myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/ejh.13316","article-title":"Estimation of Minimally Important Differences and Responder Definitions for EORTC QLQ-MY20 Scores in Multiple Myeloma Patients","volume":"103","author":"Sully","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1182\/blood.V118.21.4184.4184","article-title":"Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05","volume":"118","author":"Weiss","year":"2011","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: Properties, Applications, and Interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_50","unstructured":"FACIT Group (2023, June 15). FACT-MM: Functional Assessment of Cancer Therapy\u2014Multiple Myeloma. Available online: https:\/\/www.facit.org\/measures\/FACT-MM."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.jval.2020.04.1785","article-title":"PCN324 Minimal Clinically Important Difference (MCID) for the Functional Assessment of Cancer Therapy\u2014Multiple Myeloma (FACT-MM): Two Approaches","volume":"23","author":"Breeze","year":"2020","journal-title":"Value Health"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-6-13","article-title":"Validation of the M. D. Anderson Symptom Inventory Multiple Myeloma Module","volume":"6","author":"Jones","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing Symptom Distress in Cancer Patients: The M.D. Anderson Symptom Inventory","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Osborne, T.R., Ramsenthaler, C., Schey, S.A., Siegert, R.J., Edmonds, P.M., and Higginson, I.J. (2015). Improving the Assessment of Quality of Life in the Clinical Care of Myeloma Patients: The Development and Validation of the Myeloma Patient Outcome Scale (MyPOS). BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1261-6"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2040620720955002","DOI":"10.1177\/2040620720955002","article-title":"Quality-of-Life Issues and Symptoms Reported by Patients Living with Haematological Malignancy: A Qualitative Study","volume":"11","author":"Goswami","year":"2020","journal-title":"Ther. Adv. Hematol"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3389\/fphar.2020.00209","article-title":"Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity","volume":"11","author":"Goswami","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2217\/cer-2018-0108","article-title":"Paper and Electronic Versions of HM-PRO, a Novel Patient-Reported Outcome Measure for Hematology: An Equivalence Study","volume":"8","author":"Goswami","year":"2019","journal-title":"J. Comp. Eff. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"571066","DOI":"10.3389\/fphar.2020.571066","article-title":"Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO","volume":"11","author":"Goswami","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3389\/fphar.2020.01308","article-title":"Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study","volume":"11","author":"Goswami","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood-2018-99-117094","article-title":"Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies","volume":"132","author":"Goswami","year":"2018","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy Scale: Development and Validation of the General Measure","volume":"11","author":"Cella","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_62","unstructured":"FACIT Group (2023, June 15). FACT-BMT: Functional Assessment of Cancer Therapy\u2014Bone Marrow Transplantation. Available online: https:\/\/www.facit.org\/Measures\/FACT-BMT."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.bmt.1703313","article-title":"Translation and Validation of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Version 4 Quality of Life Instrument into Traditional Chinese","volume":"29","author":"Lau","year":"2002","journal-title":"Bone Marrow Transpl."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","article-title":"Measuring Fatigue and Other Anemia-Related Symptoms with the Functional Assessment of Cancer Therapy (FACT) Measurement System","volume":"13","author":"Yellen","year":"1997","journal-title":"J. Pain Symptom Manag."},{"key":"ref_65","unstructured":"FACIT Group (2023, June 15). FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue. Available online: https:\/\/www.facit.org\/Measures\/FACIT-F."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1182\/blood-2019-123056","article-title":"Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) in Patients with Chronic Lymphocytic Leukemia (CLL)","volume":"134","author":"Eek","year":"2019","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital Anxiety and Depression Scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1477-7525-1-29","article-title":"The Hospital Anxiety And Depression Scale","volume":"1","author":"Snaith","year":"2003","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jpsychores.2003.10.015","article-title":"Psychometric Study of Quality of Life Instruments Used during Hospitalization for Stem Cell Transplantation","volume":"57","author":"Prieto","year":"2004","journal-title":"J. Psychosom. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0022-3999(96)00216-4","article-title":"International Experiences with the Hospital Anxiety and Depression Scale\u2013A Review of Validation Data and Clinical Results","volume":"42","author":"Herrmann","year":"1997","journal-title":"J. Psychosom. Res."},{"key":"ref_71","unstructured":"National Institutes of Health, and National Cancer Institute (2023, July 12). Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events, Available online: https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/17407745221093922","article-title":"Methodological Standards for Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Cancer Clinical Trials","volume":"19","author":"Basch","year":"2022","journal-title":"Clin. Trials"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00019514-199402040-00006","article-title":"Data Collection Strategies for Patient-Reported Information","volume":"2","author":"Cella","year":"1994","journal-title":"Qual. Manag. Health Care"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/17407745221093935","article-title":"Timing Is Everything: The Importance of Patient-Reported Outcome Assessment Frequency When Characterizing Symptomatic Adverse Events","volume":"19","author":"Bhatnagar","year":"2022","journal-title":"Clin. Trials"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"100304","DOI":"10.1016\/j.jcpo.2021.100304","article-title":"Health-Related Quality of Life Data Collected in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Clinical Trials","volume":"30","author":"Raymakers","year":"2021","journal-title":"J. Cancer Policy"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/00273171.2015.1068157","article-title":"Addressing Item-Level Missing Data: A Comparison of Proration and Full Information Maximum Likelihood Estimation","volume":"50","author":"Mazza","year":"2015","journal-title":"Multivar. Behav. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jval.2013.04.001","article-title":"Reporting of Patient-Reported Outcomes in Randomized Trials: The CONSORT PRO Extension","volume":"16","author":"Patrick","year":"2013","journal-title":"Value Health"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"CONSORT PRO Group Reporting of Patient-Reported Outcomes in Randomized Trials: The CONSORT PRO Extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11136-012-0252-1","article-title":"Patient-Reported Outcomes in Randomized Clinical Trials: Development of ISOQOL Reporting Standards","volume":"22","author":"Brundage","year":"2013","journal-title":"Qual. Life Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(11)61256-7","article-title":"Reporting Quality of Life in Clinical Trials: A CONSORT Extension","volume":"378","author":"Calvert","year":"2011","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1097\/MLR.0000000000001111","article-title":"Can Methods Developed for Interpreting Group-Level Patient-Reported Outcome Data Be Applied to Individual Patient Management?","volume":"57","author":"King","year":"2019","journal-title":"Med. Care"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11136-012-0175-x","article-title":"Methods for Interpreting Change over Time in Patient-Reported Outcome Measures","volume":"22","author":"Wyrwich","year":"2013","journal-title":"Qual. Life Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/sc.2014.232","article-title":"Challenges for Defining Minimal Clinically Important Difference (MCID) after Spinal Cord Injury","volume":"53","author":"Wu","year":"2015","journal-title":"Spinal Cord."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting Clinical Trial Data in Multiple Myeloma: Translating Findings to the Real-World Setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5764\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:35:35Z","timestamp":1760132135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":84,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cancers15245764"],"URL":"https:\/\/doi.org\/10.3390\/cancers15245764","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]}}}